Dune Medical Devices said today it is relocating its US headquarters to Alpharetta, Ga., near Atlanta, from Paoli, Penn. as the company looks to expand its portfolio and improve uptake and reimbursement for its MarginProbe device.
The MarginProbe is a breast cancer surgical device designed for real-time detection of cancer in breast conserving surgeries, the company said.
The system uses the company’s proprietary radiofrequency spectroscopy technology to help surgeons identify microscopic residual cancer at surgical margins during surgery.
“Dune’s proprietary technology is already demonstrating high value by improving outcomes and reducing overall costs. Having a proven, commercialized, investable company like Dune Medical select Atlanta is a testament to the strength of our local and regional medtech ecosystem,” GCMI & T3 Labs CEO Tiffany Wilson said in a prepared statement.
Dune Medical said the move to Atlanta would expand the pool of candidates and applicants for corporate positions, and could increase the company’s ability to obtain extra funding.
“Atlanta’s high concentration of hospitals, engineers and medtech infrastructure will support MarginProbe’s march to standard of care status for breast cancer lumpectomy candidates as well as the efficient development and commercialization of other applications of our RF Spectroscopy platform,” Dune Medical CEO Lori Chmura said in a press release.
Last month, Dune Medical said it raised another $12 million it plans to use to expand the indications for the radiofrequency spectroscopy technology used in its MarginProbe cancer detection device.
The $12.3 million round was led by Canepa Healthcare, ATON Partners and the Kraft Group, Dune Medical said.
Registration is open for DeviceTalks Boston! Join us on June 5-6, 2019, as we explore the trends and technology that are shaping the future of the medical device industry.